据界面,从阿斯利康公司获悉,企业乳腺癌领域的创新药物荃科得®(通用名:卡匹色替片)纳入2025国家医保药品目录,主要治疗HR阳性晚期乳腺癌。卡匹色替于今年4月在中国获批。
据界面,从阿斯利康公司获悉,企业乳腺癌领域的创新药物荃科得®(通用名:卡匹色替片)纳入2025国家医保药品目录,主要治疗HR阳性晚期乳腺癌。卡匹色替于今年4月在中国获批。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.